Adaptive Biotechnologies Corp Net Income
| ADPT Stock | USD 15.54 0.08 0.51% |
As of the 12th of February 2026, Adaptive Biotechnologies shows the mean deviation of 2.93, and Risk Adjusted Performance of 0.0396. Adaptive Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Adaptive Biotechnologies Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 8.1553 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -143.6 M | -150.8 M | |
| Net Loss | -180.2 M | -189.2 M | |
| Net Loss | -143.6 M | -150.8 M | |
| Net Loss | (0.39) | (0.41) | |
| Net Income Per E B T | 1.00 | 0.80 |
Adaptive | Net Income | Build AI portfolio with Adaptive Stock |
The evolution of Net Income for Adaptive Biotechnologies Corp provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Adaptive Biotechnologies compares to historical norms and industry peers.
Latest Adaptive Biotechnologies' Net Income Growth Pattern
Below is the plot of the Net Income of Adaptive Biotechnologies Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Adaptive Biotechnologies financial statement analysis. It represents the amount of money remaining after all of Adaptive Biotechnologies Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Adaptive Biotechnologies' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (159.59 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Adaptive Net Income Regression Statistics
| Arithmetic Mean | (89,300,762) | |
| Coefficient Of Variation | (76.16) | |
| Mean Deviation | 57,874,728 | |
| Median | (46,447,000) | |
| Standard Deviation | 68,013,401 | |
| Sample Variance | 4625.8T | |
| Range | 182.4M | |
| R-Value | (0.59) | |
| Mean Square Error | 3217.6T | |
| R-Squared | 0.35 | |
| Significance | 0.01 | |
| Slope | (7,944,195) | |
| Total Sum of Squares | 74013.2T |
Adaptive Net Income History
Other Fundumenentals of Adaptive Biotechnologies
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Adaptive Biotechnologies Net Income component correlations
Adaptive Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Adaptive Biotechnologies is extremely important. It helps to project a fair market value of Adaptive Stock properly, considering its historical fundamentals such as Net Income. Since Adaptive Biotechnologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adaptive Biotechnologies' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adaptive Biotechnologies' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Life Sciences Tools & Services market expansion? Will Adaptive introduce new products? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share | Quarterly Revenue Growth 0.51 | Return On Assets | Return On Equity |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Adaptive Biotechnologies' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adaptive Biotechnologies represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Adaptive Biotechnologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Adaptive Biotechnologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Adaptive Biotechnologies' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Adaptive Biotechnologies.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Adaptive Biotechnologies on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Adaptive Biotechnologies Corp or generate 0.0% return on investment in Adaptive Biotechnologies over 90 days. Adaptive Biotechnologies is related to or competes with Mineralys Therapeutics, Scholar Rock, Legend Biotech, Ideaya Biosciences, Disc Medicine, Catalyst Pharmaceuticals, and Beam Therapeutics. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis... More
Adaptive Biotechnologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Adaptive Biotechnologies' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Adaptive Biotechnologies Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.69 | |||
| Information Ratio | 0.0212 | |||
| Maximum Drawdown | 29.55 | |||
| Value At Risk | (4.80) | |||
| Potential Upside | 9.94 |
Adaptive Biotechnologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adaptive Biotechnologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Adaptive Biotechnologies' standard deviation. In reality, there are many statistical measures that can use Adaptive Biotechnologies historical prices to predict the future Adaptive Biotechnologies' volatility.| Risk Adjusted Performance | 0.0396 | |||
| Jensen Alpha | 0.1651 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0267 | |||
| Treynor Ratio | 2.83 |
Adaptive Biotechnologies February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0396 | |||
| Market Risk Adjusted Performance | 2.84 | |||
| Mean Deviation | 2.93 | |||
| Semi Deviation | 3.53 | |||
| Downside Deviation | 3.69 | |||
| Coefficient Of Variation | 2587.69 | |||
| Standard Deviation | 4.64 | |||
| Variance | 21.53 | |||
| Information Ratio | 0.0212 | |||
| Jensen Alpha | 0.1651 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0267 | |||
| Treynor Ratio | 2.83 | |||
| Maximum Drawdown | 29.55 | |||
| Value At Risk | (4.80) | |||
| Potential Upside | 9.94 | |||
| Downside Variance | 13.65 | |||
| Semi Variance | 12.47 | |||
| Expected Short fall | (3.89) | |||
| Skewness | 0.6843 | |||
| Kurtosis | 4.02 |
Adaptive Biotechnologies Backtested Returns
Adaptive Biotechnologies appears to be somewhat reliable, given 3 months investment horizon. Adaptive Biotechnologies secures Sharpe Ratio (or Efficiency) of 0.0565, which signifies that the company had a 0.0565 % return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Adaptive Biotechnologies Corp, which you can use to evaluate the volatility of the firm. Please makes use of Adaptive Biotechnologies' risk adjusted performance of 0.0396, and Mean Deviation of 2.93 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Adaptive Biotechnologies holds a performance score of 4. The firm shows a Beta (market volatility) of 0.0598, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Adaptive Biotechnologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Adaptive Biotechnologies is expected to be smaller as well. Please check Adaptive Biotechnologies' coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Adaptive Biotechnologies' price patterns will revert.
Auto-correlation | -0.17 |
Insignificant reverse predictability
Adaptive Biotechnologies Corp has insignificant reverse predictability. Overlapping area represents the amount of predictability between Adaptive Biotechnologies time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Adaptive Biotechnologies price movement. The serial correlation of -0.17 indicates that over 17.0% of current Adaptive Biotechnologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.17 | |
| Spearman Rank Test | -0.39 | |
| Residual Average | 0.0 | |
| Price Variance | 1.34 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Adaptive Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Adaptive Biotechnologies Corp reported net income of (159.59 Million). This is 146.76% lower than that of the Life Sciences Tools & Services sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 127.95% higher than that of the company.
Adaptive Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adaptive Biotechnologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adaptive Biotechnologies could also be used in its relative valuation, which is a method of valuing Adaptive Biotechnologies by comparing valuation metrics of similar companies.Adaptive Biotechnologies is currently under evaluation in net income category among its peers.
Adaptive Biotechnologies Current Valuation Drivers
We derive many important indicators used in calculating different scores of Adaptive Biotechnologies from analyzing Adaptive Biotechnologies' financial statements. These drivers represent accounts that assess Adaptive Biotechnologies' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Adaptive Biotechnologies' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.9B | 1.1B | 707.5M | 2.5B | 2.8B | 3.9B | |
| Enterprise Value | 3.9B | 1.1B | 741.2M | 2.7B | 3.1B | 4.0B |
Adaptive Biotechnologies ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Adaptive Biotechnologies' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Adaptive Biotechnologies' managers, analysts, and investors.Environmental | Governance | Social |
Adaptive Biotechnologies Institutional Holders
Institutional Holdings refers to the ownership stake in Adaptive Biotechnologies that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Adaptive Biotechnologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adaptive Biotechnologies' value.| Shares | Aristotle Atlantic Partners, Llc | 2025-06-30 | 2.9 M | Driehaus Capital Management Llc | 2025-06-30 | 2.4 M | Fred Alger Management, Llc | 2025-06-30 | 2.4 M | Blue Water Life Science Advisors, Llc | 2025-06-30 | 2.1 M | Goldman Sachs Group Inc | 2025-06-30 | 1.9 M | Bank Of America Corp | 2025-06-30 | 1.9 M | Victory Capital Management Inc. | 2025-06-30 | 1.7 M | Ing Investment Management Llc | 2025-06-30 | 1.6 M | Iron Triangle Partners Lp | 2025-06-30 | 1.5 M | Viking Global Investors Lp | 2025-06-30 | 30 M | Blackrock Inc | 2025-06-30 | 13.7 M |
Adaptive Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.0679 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 2.25 B | ||||
| Shares Outstanding | 153.78 M | ||||
| Shares Owned By Insiders | 2.05 % | ||||
| Shares Owned By Institutions | 99.76 % | ||||
| Number Of Shares Shorted | 9.03 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 11.00 X | ||||
| Price To Sales | 8.67 X | ||||
| Revenue | 276.98 M | ||||
| Gross Profit | 111.85 M | ||||
| EBITDA | (29.85 M) | ||||
| Net Income | (159.59 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 280.58 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 1.42 X | ||||
| Cash Flow From Operations | (95.21 M) | ||||
| Short Ratio | 4.65 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 20.86 | ||||
| Number Of Employees | 619 | ||||
| Beta | 2.18 | ||||
| Market Capitalization | 2.4 B | ||||
| Total Asset | 512.74 M | ||||
| Retained Earnings | (1.36 B) | ||||
| Working Capital | 185.7 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
| Net Asset | 512.74 M |
About Adaptive Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adaptive Biotechnologies Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adaptive Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adaptive Biotechnologies Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.